REFERENCES
- Campbell E. G., Weissman J. S., Vogeli C., Clarridge B. R., Abraham M., et al. Financial relationships between institutional review board members and industry. N. Engl. J. Med. 2006; 355: 2321–2329
- Beck T. M., Ciociola A. A., Jones S. E., Harvey W. H., Tchekmedyian N. S., et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Ann. Intern. Med. 1993; 118: 407–413
- Cassileth P. A., Lusk E. J., Torri S., DiNubile N., Gerson S. L. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch. Intern. Med. 1983; 143(7)1347–1349
- Markman M., Sheidler V., Ettinger D. S., Quaskey S. A., Mellits E. D. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N. Engl. J. Med. 1984; 311(9)549–552
- Rose P. G., Maxson J. H., Fusco N., Mossbruger K., Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol. Oncol. 2001; 82(2)323–328
- Campos S. M., Penson R. T., Mays A. R., Berkowitz R. S., Fuller A. F., et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol. 2001; 81(2)206–212
- Rodriguez M., Rose P. G. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol. Oncol. 2001; 83(2)257–262
- Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., Safra T., Phase I I. study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. 2004; 95(3)686–690
- Alberts D. S., Liu P. Y., Hannigan E. V., O'Toole R., Williams S. D., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996; 335(26)1950–1955
- Markman M., Bundy B. N., Alberts D. S., Fowler J. M., Clark-Pearson D. L., et al. Phase I II trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001; 19(4)1001–1007
- Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006; 354(1)34–43
- Trimble E. L., Alvarez R. D. Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol. Oncol. 2006; 103: S18–S19, (2 Suppl 1)